MBX — MBX Biosciences Share News
0.000.00%
Last trade - 00:00Brief: MBX Biosciences Announces Additions To Leadership Team
Brief: Mbx Biosciences Completes Enrollment In Phase 2 Avail Trial Of Mbx 2109 (Canvuparatide) For Hypoparathyroidism
Weight-loss drug developer Metsera raises $275 million in US IPO (updated)
Weight-loss drug developer Metsera raises $275 million in US IPO
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO (updated)
Weight-loss drug developer Metsera reveals wider loss in US IPO filing (updated)
Brief: MBX Biosciences Announces Positive Phase 1 Topline Results For MBX 1416 To Treat Post-Bariatric Hypoglycemia
Brief: MBX Biosciences Announces Last Subject Last Visit In Phase 1 Trial
Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO (updated)
U.S. RESEARCH ROUNDUP-Humana, Portillos, Waters
Brief: Orbimed Advisors Reports 12.0% Stake In MBX Biosciences As Of Sept 16 - SEC Filing
Brief: Deep Track Capital Reports 9.48% Passive Stake In MBX Biosciences
MBX Biosciences shares surge 44% in blockbuster Nasdaq debut (updated)